Skip to main content

Proteinase-activated receptor-2 (PAR-2) expression on inflammatory cells in severe asthma


PAR-2, a G-coupled receptor activated by serine proteinases, is widely expressed in the human body and is involved in inflammation. We have shown that PAR-2 activation in the airways plays a pathogenetic role in mouse models of asthma. PAR-2 expression is increased in the epithelium of asthmatic subjects, but its expression on immune and inflammatory cells of asthmatic individuals has not been. Severe asthma has different phenotypic characteristics from mild-moderate disease. In this study we compared PAR-2 expression on immune cells between subjects with mild/moderate and severe asthma.


A total of 36 asthma subjects (24 mild/moderate; 12 severe by ATS guidelines) were recruited at the University of Alberta Hospital and peripheral blood obtained. PAR-2 expression was analyzed by flow cytometry and qRT-PCR in whole blood.


There were no differences in the % of eosinophils, neutrophils or CD4+ T cells expressing PAR-2 between severe and mild/moderate asthmatics. CD14high monocytes were classified as classical (CD14++CD16-) or intermediate (CD14++CD16+). No difference in total numbers of either monocyte sub-population was noted between the two asthma groups. More intermediate monocytes from patients with severe asthma (33.6±5.1%) expressed PAR-2 compared to patients with mild/moderate asthma (22.4±4.0%, p=0.039), but there was no difference between asthma phenotypes in the percent of classical monocytes expressing PAR-2 (11.7±2.8% vs. 12.5±2.9%). PAR-2 mRNA expression was not different between severe and mild/moderate asthmatics, however, PAR-2 mRNA correlated with total dose of inhaled steroids and inversely correlated with % predicted FEV1.


PAR-2 expression is increased on intermediate monocytes in subjects with severe asthma. Intermediate monocytes are pro-inflammatory and their numbers are increased in inflammatory diseases. Our data suggest that PAR-2-mediated activation of intermediate monocytes may play a role in the pathogenesis of severe asthma, although the effects of PAR-2-mediated activation of these cells are not known.

Author information



Corresponding author

Correspondence to Harissios Vliagoftis.

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit

The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nahirney, D., Palikhe, N.S., Laratta, C. et al. Proteinase-activated receptor-2 (PAR-2) expression on inflammatory cells in severe asthma. All Asth Clin Immun 10, A50 (2014).

Download citation


  • Asthma
  • Serine Proteinase
  • Severe Asthma
  • Asthma Subject
  • Pathogenetic Role